Global Herpes Zoster Treatment Market 2019-2023

Global Herpes Zoster Treatment Market 2019-2023

About this market

With the emerging innovative vaccines for disease management, there is a growing demand for herpes zoster treatment drugs. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles. For instance, in October 2017, Shingrix was launched by GlaxoSmithKline for the treatment of shingles. The vaccine is much more effective than ZOSTAVAX, which was the only approved vaccine for shingles in older adults. Technavio’s analysts have predicted that the herpes zoster treatment market will register a CAGR of almost 14% by 2023.Market Overview

Rising incidence of herpes zoster

Factors such as exposure to ultraviolet radiation may suppress the cell-mediated immunity, which can be a major factor responsible for the growing incidence of herpes zoster. Patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing shingles, which is expected to boost the growth of the global herpes zoster treatment market.

Weak pipeline for herpes zoster

The number of herpes zoster pipeline agents are very limited despite the growing incidence of the infection worldwide, which is likely to hamper the growth of the global herpes zoster treatment market.

For the detailed list of factors that will drive and challenge the growth of the herpes zoster treatment market during the 2019-2023 period, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Abbott and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster, will provide considerable growth opportunities to herpes zoster treatment companies. Abbott, GlaxoSmithKline, Merck, and Novartis are some of the major companies covered in this report.

PRESS RELEASE

Technavio Announces the Publication of its Research Report - Global Herpes Zoster Treatment Market 2019-2023

Technavio recognizes the following company as the key player in the global herpes zoster treatment market: Abbott, GlaxoSmithKline, Merck, and Novartis.

Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the emerging innovative vaccines for disease management. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles.”

According to the report, one driver influencing this market is the driven by the rising incidences of herpes zoster. Factors such as exposure to ultraviolet radiation may suppress the cell-mediated immunity, which can be a major factor responsible for the growing incidence of herpes zoster. Patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing shingles, which is expected to boost the growth of the global herpes zoster treatment market.

Further, the report states that one challenge affecting this market is the weak pipeline for herpes zoster. The number of herpes zoster pipeline agents are very limited despite the growing incidence of the infection worldwide, which is likely to hamper the growth of the global herpes zoster treatment market.

Companies Mentioned

Abbott

GlaxoSmithKline

Merck

Novartis